Le Lézard
Classified in: Health
Subjects: NPT, AVO

Prevent Blindness to Hold Seventeenth Annual "Eyes on Capitol Hill" Advocacy Event


CHICAGO, Feb. 25, 2022 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's oldest non-profit eye health and safety organization, will be holding its seventeenth annual Eyes on Capitol Hill advocacy day as a virtual event on March 1-2, 2022. Continuing its mission as a patient advocacy group, Prevent Blindness created the Eyes on Capitol Hill program specifically to provide patients, caregivers, allied personnel, and medical professionals direct access to their elected officials, in an effort to educate lawmakers and their staff on a variety of vision health issues, including vision health inequities, the need for improved vision surveillance, the impact of community eye health programs, and disparities in access to affordable eyecare services.

In addition to discussing personal stories, this year's Eyes on Capitol Hill advocates will ask elected officials to:

Advocates will also ask Congress to pass a final Fiscal Year 2022 bill and include the proposed funding level of $2 million to the VHI. A continuing resolution is set to expire on March 11.

"One of our most important events of the year, Eyes on Capitol Hill is essential to ensure that our policymakers are made aware of the significant impact that vision loss and blindness may have on the ability to succeed in the classroom, continue to work and live independently, as well as maintain mental health and quality of life," said Jeff Todd, president and CEO of Prevent Blindness. "Through improved national surveillance methods, spread of effective community vision programs, and access to quality eyecare services and treatments, we can work together to help save sight in children, adults and seniors."

For more information on Eyes on Capitol Hill, or Prevent Blindness and its advocacy initiatives, please visit preventblindness.org/advocacy-initiatives/.

About Prevent Blindness
Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

###

Media Contact

Sarah Hecker, Prevent Blindness, 3123636035, [email protected]

Twitter

 

SOURCE Prevent Blindness


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: